Document Detail

Melanoma prognostics and personalized therapeutics at a crossroad.
MedLine Citation:
PMID:  23318787     Owner:  NLM     Status:  In-Data-Review    
Melanoma has recently emerged as a poster child for targeted therapies and immunotherapies, with game-changing BRAF and immune checkpoint inhibitors now in clinical trials and with approved clinical indications. One highly anticipated use of novel therapeutic agents is in the adjuvant setting. Adjuvant BRAF and/or immune checkpoint inhibition may positively affect the survival of melanoma patients diagnosed at earlier stages but still at high risk for postsurgical relapses. BRAF V600 mutations and, potentially, melanoma-associated immunity are predictive biomarkers for responses to these novel therapies. Emerging evidence points to these predictive biomarkers doubling as prognostic biomarkers for high-risk stage III patients, promising to help stratify these patients for the application of novel adjuvant therapies.
Roger S Lo
Related Documents :
23192297 - Comparison of disease-specific survival in the united states and korea after resection ...
23786457 - Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid l...
10494517 - Nasopharyngeal cancer.
23749307 - Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an anal...
3600047 - Analysis of survival data on aging rat cohorts: pitfalls and some practical considerati...
20594857 - Cyberknife radiosurgery for management of intracranial perineural spread of cutaneous m...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  133     ISSN:  1523-1747     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  292-5     Citation Subset:  IM    
1] Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA [2] Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent.
Next Document:  Nitroarachidonic acid prevents NADPH oxidase assembly and superoxide radical production in activated...